408 related articles for article (PubMed ID: 26426300)
1. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
Leone M; Iacoviello M
Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
[TBL] [Abstract][Full Text] [Related]
4. [The involvement of galectin-3 in heart failure].
Kałan M; Witczak A; Mosiewicz J; Donica H
Postepy Hig Med Dosw (Online); 2015 Sep; 69():1107-13. PubMed ID: 26400896
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
6. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
8. Renal function largely influences Galectin-3 prognostic value in heart failure.
Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3, a prognostic marker--and a therapeutic target?
Pereira AR; Menezes Falcão L
Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
[TBL] [Abstract][Full Text] [Related]
11. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure.
Lala RI; Lungeanu D; Darabantiu D; Pilat L; Puschita M
Herz; 2018 Mar; 43(2):146-155. PubMed ID: 28235980
[TBL] [Abstract][Full Text] [Related]
13. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.
Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of galectin-3 in patients with heart failure.
Bošnjak I; Selthofer-Relatić K; Včev A
Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profile provides prognostic value better than galectin-3 in patients with heart failure.
Wang CH; Cheng ML; Liu MH; Kuo LT; Shiao MS
J Cardiol; 2017 Jul; 70(1):92-98. PubMed ID: 28318874
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
Felker GM; Fiuzat M; Shaw LK; Clare R; Whellan DJ; Bettari L; Shirolkar SC; Donahue M; Kitzman DW; Zannad F; Piña IL; O'Connor CM
Circ Heart Fail; 2012 Jan; 5(1):72-8. PubMed ID: 22016505
[TBL] [Abstract][Full Text] [Related]
17. Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients.
Behnes M; Bertsch T; Weiss C; Ahmad-Nejad P; Akin I; Fastner C; El-Battrawy I; Lang S; Neumaier M; Borggrefe M; Hoffmann U
Int J Cardiol; 2016 Jan; 203():398-406. PubMed ID: 26539964
[TBL] [Abstract][Full Text] [Related]
18. [Galectin 3--a new biomarker for diagnostics and outcome of chronic heart failure].
Lakomkin SV; Skvortsov AA; Goriunova TV; Masenko VP; Tereshchenko SN
Kardiologiia; 2012; 52(3):45-52. PubMed ID: 22839443
[TBL] [Abstract][Full Text] [Related]
19. Soluble ST2 and galectin-3 in heart failure.
Shah RV; Januzzi JL
Clin Lab Med; 2014 Mar; 34(1):87-97, vi-vii. PubMed ID: 24507789
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
Ho JE; Liu C; Lyass A; Courchesne P; Pencina MJ; Vasan RS; Larson MG; Levy D
J Am Coll Cardiol; 2012 Oct; 60(14):1249-56. PubMed ID: 22939561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
